Orchard Therapeutics announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company. Mr. Parker is a seasoned commercial leader with more than 20 years of experience in the healthcare and biotech industry, including deep rare disease and gene therapy experience. Mr. Parker’s previous positions include commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic planning for their gene therapy business. Most recently, Mr. Parker served as Orchard’s senior vice president and general manager for North America. Mr. Parker joined Orchard from PTC Therapeutics, where he served as vice president and general manager for the U.S. organization. In this role, he oversaw commercial operations, marketing, and market access activities, and also actively engaged with the policy community on health reform and modernization efforts.